SCHEMBL29401459

SCHEMBL29401459

COC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(C)=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.71
MEN1 O00255 4/20 0.71
HCRTR1 O43613 1/20 0.71
TACR1 P25103 5/20 0.71
MAPT P10636 3/20 0.66
TP53 P04637 2/20 0.66
KDM4E B2RXH2 1/20 0.66
ALDH1A1 P00352 1/20 0.66
LMNA P02545 1/20 0.66
CYP1A2 P05177 1/20 0.66
POLB P06746 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2D6 P10635 1/20 0.66
CYP2C9 P11712 1/20 0.66
NFKB1 P19838 1/20 0.66
APEX1 P27695 1/20 0.66
CYP2C19 P33261 1/20 0.66
THPO P40225 1/20 0.66
BLM P54132 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468840 1.00 KMT2A (0.71) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL3184939 1.00 KMT2A (0.71) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL29138492 0.90 TACR1 (0.63) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL16626132 0.90 TACR1 (0.63) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL6362124 0.90 TACR1 (0.63) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL6355051 0.90 TACR1 (0.63) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL850315 0.90 TACR1 (0.74) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL3185689 0.90 TACR1 (0.74) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL5385762 0.90 TACR1 (0.72) KMT2AMEN1HCRTR1TACR1MAPT
SCHEMBL30359404 0.90 TACR1 (0.72) KMT2AMEN1HCRTR1TACR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4345104-B1 METHOD FOR PREPARING LIRAGLUTIDE BACHEM HOLDING AG (CH) 2024-08-28 EP claimed
US-12577274-B2 Manufacture of glucagon peptides BACHEM HOLDING AG (CH) 2026-03-17 US disclosed
WO-2025229200-A1 MANUFACTURE OF DISULFIDE BONDED PEPTIDES BACHEM HOLDING AG (CH) 2025-11-06 WO disclosed
EP-3728304-B1 SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES BACHEM HOLDING AG (CH) 2025-02-12 EP disclosed
US-20240316223-A1 Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-09-26 US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
CN-118515597-A Visible light mediated tryptophan indole C-2 site selective arylation modification method and application thereof 中国科学院深圳先进技术研究院 2024-08-20 CN disclosed
WO-2024081692-A1 MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2024-04-18 WO disclosed
CN-111670194-B Preparation of glucagon peptides 巴赫姆控股股份公司 2024-01-26 CN disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
WO-2023114615-A1 OXIDATIVE CYCLIZATION REAGENTS FOR CHEMOSELECTIVE TRYPTOPHAN BIOCONJUGATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-22 WO disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
EP-3746466-B1 MANUFACTURE OF GLUCAGON PEPTIDES BACHEM AG (CH) 2022-11-23 EP disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 US disclosed
EP-3433267-B1 METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES BACHEM HOLDING AG (CH) 2022-08-24 EP disclosed
US-20220259258-A1 A Manufacturing Process for Peptide and Protein Production MYTIDE THERAPEUTICS, INC. 2022-08-18 US disclosed
EP-3983424-A1 A MANUFACTURING PROCESS FOR PEPTIDE AND PROTEIN PRODUCTION Mytide Therapeutics, Inc. (US) 2022-04-20 EP disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577274-B2 Manufacture of glucagon peptides IAPP, GLP1R, GCG KMT2A 4018/4885MEN1 957/4885HCRTR1 2791/4885
US-20240316223-A1 Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation TDO2, TPH1, TPH2 KMT2A 2305/4885MEN1 3689/4885HCRTR1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.